Lexaria Bioscience’s (CSE: LXX) (OTCQX: LXRP) DehydraTECH™ Applicable to Multiple Industries
Active investigation phase in the EU, Canada, China, Japan and India Forming four new wholly owned subsidiaries Seeks to acquire an equitable tax treatment Cannabinoids are poorly absorbed by the body’s gastrointestinal tract, a trait that Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQX: LXRP) lipophilic enhancement technology DehydraTECH™ is changing. Previously, consumers have turned to cannabis smoking to achieve higher effectiveness. However, human clinical studies have shown DehydraTECH™ to have a quick rate of absorption, allowing users to avoid the risks associated with smoking. DehydraTECH™ offers improved taste and smell, with effects felt within 15 to 20 minutes as opposed to…